✦ LIBER ✦

291 Phase I/II multicentre study with the monoclonal antibody WX-G250 in combination with interferon α-2A in metastatic renal cell carcinoma

✍ Scribed by M. Siebels; K. Rohrmann; R. Oberneder; A. Hofstetter; Z. Varga; R. Hoffmann; M. Kindler; S. Melchior; C. Mala; J. Beck

Book ID: 118645505
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 220 KB
Volume: 3
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(04)90291-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial with monoclonal antibod

A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma

✍ I. Bleumer; J. Beck; R. Hofmann; W. Kruit; S. Warnaar; C. Mala; S. Ullrich; C. H 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 188 KB

A phase I/II trial with chimeric monoclo

A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low dose interleukin-2 for patients with metastatic renal cell carcinoma

✍ I. Bleumer; J. Beck; Oosterwijk; C. Mala; S. Ullrich; P.F.A. Mulders 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 199 KB

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

Phase I/II study of thalidomide in combi

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Recombinant interferon α-2A combined wit

Recombinant interferon α-2A combined with prednisone in metastatic renal-cell carcinoma: Treatment results, serum interferon levels and the development of antibodies

✍ Sophie D. Fosså; Gustav Lehne; Ragnhild Gunderson; Unni Hielmaas; Eduard E. Hold 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 375 KB 👁 1 views

Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-a 2a (IFN) + prednisone (P). Four of 24 subsequent patients responded to IFN + P (combined response rate 19%). The median response duration was 8 months (3 to 30 months). The one-year sur

Recombinant interferon-alpha combined wi

Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma reduced toxicity without reduction of the response rate—a phase II study

✍ Sophie D. Fosså; Ragnhild Gunderson; Brit Moe 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views